Regulation of intracellular human immunodeficiency virus type-1 protease activity

Virology

Volumn 244, Issue 1, 1998, Pages 87-96

  Gatlin, Joel ^a   Arrigo, Salvatore J ^a   Schmidt, Michael G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN PRECURSOR; PROTEINASE;

ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE; RNA VIRUSES;

EID: 0032565396     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9083     Document Type: Article

References (52)

1. Arrigo S. J., Chen I. S. Y. Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/vpu-2 RNAs. Genes Dev. 5:1991;808-819.
2. Arrigo S. J., Huffman K. Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers. J. Virol. 69:1995;5988-5994.
3. Ashorn P., McQuade T. J., Thaisrivongs S., Tomasselli A. G., Tarpley W. G., Moss B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc. Natl. Acad. Sci. USA. 87:1990;7472-7476.
4. Bryant M., Ratner L. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc. Natl. Acad. Sci. USA. 87:1990;523-527.
5. Bukovsky A., Gottlinger H. Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease. J. Virol. 70:1996;6820-6825.
6. Campbell L. H., Borg K. T., Arrigo S. J. Differential effects of intronic and exonic locations of the human immunodeficiency virus type 1 Rev-responsive element. Virology. 219:1996;423-431.
7. Chazal N., Carriere C., Gay B., Boulanger P. Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells. J. Virol. 68:1994;111-122.
8. Dorfman T., Bukovsky A., Ohagen A., Hoglund S., Gottlinger H. G. Functional domains of the capsid protein of human immunodeficiency virus type 1. J. Virol. 68:1994;8180-8187.
9. Erickson V. S., Manfredi J., Viitanen P., Tribe D. E., Tritch R., Hutchison C. d., Loeb D. D., Swanstrom R. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res. Hum. Retroviruses. 5:1989;577-591.
10. Franke E. K., Yuan H. E., Bossolt K. L., Goff S. P., Luban J. Specificity and sequence requirements for interactions between various retroviral Gag proteins. J. Virol. 68:1994;5300-5305.
11. Gatlin J., Campbell L. H., Schmidt M. G., Arrigo S. J. Direct-rapid (DR) mutagenesis of large plasmids using PCR. Biotechniques. 19:1995;559-564.
12. Gheysen D., Jacobs E., de F. F., Thiriart C., Francotte M., Thines D., De W. M. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell. 59:1989;103-112.
13. Gottlinger H. G., Sodroski J. G., Haseltine W. A. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 86:1989;5781-5785.
14. Gowda S. D., Stein B. S., Engleman E. G. Identification of protein intermediates in the processing of the p55 HIV-1 gag precursor in cells infected with recombinant vaccinia virus. J. Biol. Chem. 264:1989;8459-8462.
15. Hayashi T., Shioda T., Iwakura Y., Shibuta H. RNA packaging signal of human immunodeficiency virus type 1. Virology. 188:1992;590-599.
16. Hong S. S., Boulanger P. Assembly-defective point mutants of the human immunodeficiency virus type 1 Gag precursor phenotypically expressed in recombinant baculovirus-infected cells. J. Virol. 67:1993;2787-2798.
17. Huang M., Martin M. A. Incorporation of Pr160(gag-pol) into virus particles requires the presence of both the major homology region and adjacent C-terminal capsid sequences within the Gag-Pol polyprotein. J. Virol. 71:1997;4472-4478.
18. Jacks T., Power M. D., Masiarz F. R., Luciw P. A., Barr P. J., Varmus H. E. Characterization of ribosomal frameshifting in HIV-1gag-polexpression. Nature. 331:1988;280-283.
19. Kaplan A. H., Manchester M., Swanstrom R. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol. 68:1994;6782-6786.
20. Kaplan A. H., Swanstrom R. The HIV-1 gag precursor is processed via two pathways: implications for cytotoxicity. Biomed. Biochim. Acta. 50:1991a;647-653.
21. Kaplan A. H., Swanstrom R. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc. Natl. Acad. Sci. USA. 88:1991b;4528-4532.
22. Karacostas V., Wolffe E. J., Nagashima K., Gonda M. A., Moss B. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology. 193:1993;661-671.
23. Kohl N. E., Emini E. A., Schleif W. A., Davis L. J., Heimbach J. C., Dixon R. A., Scolnick E. M., Sigal I. S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA. 85:1988;4686-4690.
24. Kramer R. A., Schaber M. D., Skalka A. M., Ganguly K., Wong-Staal F., Reddy E. P. HTLV-IIIgagprotein is processed in yeast cells by the viruspol-protease. Science. 231:1986;1580-1584.
25. Krausslich H. G. Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc. Natl. Acad. Sci. USA. 88:1991;3213-3217.
26. Krausslich H. G. Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation. J. Virol. 66:1992;567-572.
27. Krausslich H. G., Ochsenbauer C., Traenckner A. M., Mergener K., Facke M., Gelderblom H. R., Bosch V. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology. 192:1993;605-617.
28. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
29. Lapatto R., Blundell T., Hemmings A., Overington J., Wilderspin A., Wood S., Merson J. R., Whittle P. J., Danley D. E., Geoghegan K. F., et a. l. X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes. Nature. 342:1989;299-302.
30. Lillehoj E. P., Salazar F. H., Mervis R. J., Raum M. G., Chan H. W., Ahmad N., Venkatesan S. Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus. J. Virol. 62:1988;3053-3058.
31. Luban J., Alin K. B., Bossolt K. L., Humaran T., Goff S. P. Genetic assay for multimerization of retroviral gag polyproteins. J. Virol. 66:1992;5157-5160.
32. Luukkonen B. G., Fenyo E. M., Schwartz S. Overexpression of human immunodeficiency virus type 1 protease increases intracellular cleavage of Gag and reduces virus infectivity. Virology. 206:1995;854-865.
33. McDermott J., Farrell L., Ross R., Barklis E. Structural analysis of human immunodeficiency virus type 1 Gag protein interactions, using cysteine-specific reagents. J. Virol. 70:1996;5106-5114.
34. Mergener K., Facke M., Welker R., Brinkmann V., Gelderblom H. R., Krausslich H. G. Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Virology. 186:1992;25-39.
35. Navia M. A., Fitzgerald P. M., McKeever B. M., Leu C. T., Heimbach J. C., Herber W. K., Sigal I. S., Darke P. L., Springer J. P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature. 337:1989;615-620.
36. Park J., Morrow C. D. Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J. Virol. 65:1991;5111-5117.
37. Park J., Morrow C. D. The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles. J. Virol. 66:1992;6304-6313.
38. Partin K., Krausslich H. G., Ehrlich L., Wimmer E., Carter C. Mutational analysis of a native substrate of the human immunodeficiency virus type 1 proteinase. J. Virol. 64:1990;3938-3947.
39. Peng C., Ho B. K., Chang T. W., Chang N. T. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. 63:1989;2550-2556.
40. Pettit S. C., Simsic J., Loeb D. D., Everitt L., Hutchison C. d., Swanstrom R. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J. Biol. Chem. 266:1991;14539-14547.
41. Prince A. M., Reesink H., Pascual D., Horowitz B., Hewlett I., Murthy K. K., Cobb K. E., Eichberg J. W. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res. Hum. Retroviruses. 7:1991;971-973.
42. Royer M., Hong S. S., Gay B., Cerutti M., Boulanger P. Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells. J. Virol. 66:1992;3230-3235.
43. Smith A. J., Srinivasakumar N., Hammarskjold M. L., Rekosh D. Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles. J. Virol. 67:1993;2266-2275.
44. Srinivasakumar N., Hammarskjold M. L., Rekosh D. Characterization of deletion mutations in the capsid region of human immunodeficiency virus type 1 that affect particle formation and Gag-Pol precursor incorporation. J. Virol. 69:1995;6106-6114.
45. Stephens E. B., Compans R. W. Assembly of animal viruses at cellular membranes. Annu. Rev. Microbiol. 42:1988;489-516.
46. Tritch R. J., Cheng Y. E., Yin F. H., Erickson V. S. Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein. J. Virol. 65:1991;922-930.
47. Trono D., Feinberg M. B., Baltimore D. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell. 59:1989;113-120.
48. Wilcox C., Hu J. S., Olson E. N. Acylation of proteins with myristic acid occurs cotranslationally. Science. 238:1987;1275-1278.
49. Wills J. W., Craven R. C. Form, function, and use of retroviral gag proteins. AIDS. 5:1991;639-654.
50. Wilson W., Braddock M., Adams S. E., Rathjen P. D., Kingsman S. M., Kingsman A. J. HIV expression strategies: Ribosomal frameshifting is directed by a short sequence in both mammalian and yeast systems. Cell. 55:1988;1159-1169.
51. Zhang Y. Q., Barklis E. Effects of nucleocapsid mutations on human immunodeficiency virus assembly and RNA encapsidation. J. Virol. 71:1997;6765-6776.
52. Zybarth G., Carter C. Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing. J. Virol. 69:1995;3878-3884.